Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22474755 | 0.86 | ALDH1A1 (0.71) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL15014489 | 0.86 | ALDH1A1 (0.71) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL478307 | 0.86 | ALDH1A1 (0.71) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL13931196 | 0.83 | ALDH1A1 (0.67) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL3741164 | 0.82 | MEN1 (0.69) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL15224143 | 0.81 | ALDH1A1 (0.65) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL19240755 | 0.81 | ALDH1A1 (0.64) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL15613653 | 0.79 | KMT2A (0.81) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL8414529 | 0.79 | KMT2A (0.81) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL10274487 | 0.79 | KMT2A (0.81) | ALDH1A1LMNAKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280034-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-7338969-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070208012-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070203128-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070196340-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197492-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070184014-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070093534-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197492-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | ALDH1A1 4721/4885LMNA 2846/4885KMT2A 4236/4885 |
| US-20070203128-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | ALDH1A1 4721/4885LMNA 2846/4885KMT2A 4236/4885 |
| US-20070093534-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | ALDH1A1 3931/4885LMNA 3949/4885KMT2A 2108/4885 |
| US-20070208012-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | ALDH1A1 4721/4885LMNA 2846/4885KMT2A 4236/4885 |
| US-20100280034-A1 | Modulation of pathogenicity | NR1H4, NR1I3, NR1H2 | ALDH1A1 3931/4885LMNA 3949/4885KMT2A 2108/4885 |
| US-20070184014-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | ALDH1A1 4721/4885LMNA 2846/4885KMT2A 4236/4885 |
| US-20070196340-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | ALDH1A1 3931/4885LMNA 3949/4885KMT2A 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.